A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity

A. Gibb; P. Johnson; A. Greystoke; M. Ranson; K. Linton; C. Dive; S. Neeson; A. Pettit; E. Smith; A. Lister; T. Illidge; J. Radford

doi:10.1093/annonc/mdr223

A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity

A. Gibb
, P. Johnson
, A. Greystoke
, M. Ranson
, K. Linton
, C. Dive
, S. Neeson
, A. Pettit
, E. Smith
, A. Lister
, T. Illidge
, J. Radford

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	286
Pages (from-to)	iv180
Number of pages	1
Journal	Annals of Oncology
Volume	22
Issue number	Supplement 4
DOIs	https://doi.org/10.1093/annonc/mdr223
Publication status	Published - Jun 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdr223

Cite this

Gibb, A., Johnson, P., Greystoke, A., Ranson, M., Linton, K., Dive, C., Neeson, S., Pettit, A., Smith, E., Lister, A., Illidge, T., & Radford, J. (2011). A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity. Annals of Oncology, 22(Supplement 4), iv180. Article 286. https://doi.org/10.1093/annonc/mdr223

@article{8be8a9b1dce649c8b2b36b7ebd4ccd65,

title = "A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity",

author = "A. Gibb and P. Johnson and A. Greystoke and M. Ranson and K. Linton and C. Dive and S. Neeson and A. Pettit and E. Smith and A. Lister and T. Illidge and J. Radford",

year = "2011",

month = jun,

doi = "10.1093/annonc/mdr223",

language = "English",

volume = "22",

pages = "iv180",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "Supplement 4",

}

Gibb, A, Johnson, P, Greystoke, A, Ranson, M, Linton, K, Dive, C, Neeson, S, Pettit, A, Smith, E, Lister, A, Illidge, T & Radford, J 2011, 'A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity', Annals of Oncology, vol. 22, no. Supplement 4, 286, pp. iv180. https://doi.org/10.1093/annonc/mdr223

A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity. / Gibb, A.; Johnson, P.; Greystoke, A. et al.
In: Annals of Oncology, Vol. 22, No. Supplement 4, 286, 06.2011, p. iv180.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity

AU - Gibb, A.

AU - Johnson, P.

AU - Greystoke, A.

AU - Ranson, M.

AU - Linton, K.

AU - Dive, C.

AU - Neeson, S.

AU - Pettit, A.

AU - Smith, E.

AU - Lister, A.

AU - Illidge, T.

AU - Radford, J.

PY - 2011/6

Y1 - 2011/6

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000291996300300&KeyUID=WOS:000291996300300

U2 - 10.1093/annonc/mdr223

DO - 10.1093/annonc/mdr223

M3 - Meeting Abstract

SN - 0923-7534

VL - 22

SP - iv180

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement 4

M1 - 286

ER -

A phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of abvd chemotherapy for Hodgkin Lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity

UN SDGs

Access to Document

Other files and links

Cite this